Clinical and Translational Oncology This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Risk of endometrial cancer after RRSO in BRCA 1/2 carriers: a multicentre cohort study
ConclusionsIn our cohort, the risk of EC inBRCA1/2 carriers after RRSO is not greater than expected. Hysterectomy is not routinely recommended for these patients. (Source: Clinical and Translational Oncology)
Source: Clinical and Translational Oncology - March 30, 2024 Category: Cancer & Oncology Source Type: research

Real-world experience with pertuzumab and trastuzumab combined with chemotherapy in neoadjuvant treatment for patients with early-stage HER2-positive breast cancer: the NEOPERSUR study
ConclusionNeoadjuvant pertuzumab and trastuzumab plus CT achieve high pCR rates in real-life patients with HER2-positive early BC, showing an acceptable safety profile. Innovative adjuvant strategies are essential in patients at high risk of distant disease recurrence. (Source: Clinical and Translational Oncology)
Source: Clinical and Translational Oncology - March 28, 2024 Category: Cancer & Oncology Source Type: research

Logistic regression and other statistical tools in diagnostic biomarker studies
AbstractA biomarker is a measured indicator of a variety of processes, and is often used as a clinical tool for the diagnosis of diseases. While the developmental process of biomarkers from lab to clinic is complex, initial exploratory stages often focus on characterizing the potential of biomarkers through utilizing various statistical methods that can be used to assess their discriminatory performance, establish an appropriate cut-off that transforms continuous data to apt binary responses of confirming or excluding a diagnosis, or establish a robust association when tested against confounders. This review aims to provid...
Source: Clinical and Translational Oncology - March 26, 2024 Category: Cancer & Oncology Source Type: research

Efficacy and safety of anlotinib plus anti-PD-1 agents in patients with refractory advanced biliary tract cancers
ConclusionsThe combination of anlotinib and PD-1 inhibitors demonstrated a promising clinical effect compared to fluoropyrimidine-based chemotherapy in the second-line treatment of refractory advanced BTCs. Liver metastases and CEA levels may serve as predictive factors for identifying patients who may benefit from AP therapy. (Source: Clinical and Translational Oncology)
Source: Clinical and Translational Oncology - March 26, 2024 Category: Cancer & Oncology Source Type: research

Multidisciplinary approach for locally advanced non-small cell lung cancer (NSCLC): 2023 expert consensus of the Spanish Lung Cancer Group GECP
ConclusionsConsensus clinical suggestions were generated on the most relevant scenarios such as diagnosis, staging and treatment of locally advanced lung cancer, which will serve to support decision-making in daily practice. (Source: Clinical and Translational Oncology)
Source: Clinical and Translational Oncology - March 26, 2024 Category: Cancer & Oncology Source Type: research

The prognostic value of vessels encapsulating tumor clusters (VETC) in patients with hepatocellular carcinoma: a systematic review and meta-analysis
ConclusionIn conclusion, the meta-analysis suggests that VETC is a significant predictor of overall survival and tumor efficacy in HCC patients and may be a valid prognostic indicator. (Source: Clinical and Translational Oncology)
Source: Clinical and Translational Oncology - March 25, 2024 Category: Cancer & Oncology Source Type: research

Elderly patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with CDK4/6 inhibitors in a multicentre cohort
ConclusionsOur RWD suggests that elderly patients, when compared to those under 70, experience similar survival outcomes and exhibit comparable tolerance for CDK4/6i therapy. (Source: Clinical and Translational Oncology)
Source: Clinical and Translational Oncology - March 22, 2024 Category: Cancer & Oncology Source Type: research

Zebrafish live imaging: a strong weapon in anticancer drug discovery and development
AbstractDeveloping anticancer drugs is a complex and time-consuming process. The inability of current laboratory models to reflect important aspects of the tumor in vivo limits anticancer medication research. Zebrafish is a rapid, semi-automated in vivo screening platform that enables the use of non-invasive imaging methods to monitor morphology, survival, developmental status, response to drugs, locomotion, or other behaviors. Zebrafish models are widely used in drug discovery and development for anticancer drugs, especially in conjunction with live imaging techniques. Herein, we concentrated on the use of zebrafish live ...
Source: Clinical and Translational Oncology - March 21, 2024 Category: Cancer & Oncology Source Type: research

Screening and treatment of latent tuberculosis in patients with solid tumors and systemic cancer therapy
DiscussionPatients with solid tumours generally have a limited life expectancy and a state of intermittent immunosuppression, resulting in a lower risk of tuberculosis reactivation than other risky  populations. There is a lack of prospective and retrospective studies analysing the benefit of screening and prophylaxis in this population. The first step is to study the incidence of active tuberculosis in this population to estimate the real magnitude of the problem. (Source: Clinical and Translational Oncology)
Source: Clinical and Translational Oncology - March 21, 2024 Category: Cancer & Oncology Source Type: research

Comparative study of weekly and three-weekly neoadjuvant carboplatin in triple-negative breast cancer: retrospective analysis in real-world settings
ConclusionsWeekly carboplatin exhibited comparable toxicity, a trend toward fewer interruptions, and similar pCR rates. Prospective studies are essential for validating these findings. (Source: Clinical and Translational Oncology)
Source: Clinical and Translational Oncology - March 21, 2024 Category: Cancer & Oncology Source Type: research

Current approaches in glioblastoma multiforme immunotherapy
This study aims to review the currently used immunotherapy approaches with their molecular mec hanisms and clinical application in GBM. (Source: Clinical and Translational Oncology)
Source: Clinical and Translational Oncology - March 21, 2024 Category: Cancer & Oncology Source Type: research

The S-REAL study: Spanish real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy
ConclusionsThese results are in line with prior published evidence and confirm the benefits of durvalumab in the treatment of LA-NSCLC patients in a real-world setting. We also observed a lower incidence of important treatment-associated toxicities, such as pneumonitis, compared with the pivotal phase III PACIFIC clinical study. (Source: Clinical and Translational Oncology)
Source: Clinical and Translational Oncology - March 21, 2024 Category: Cancer & Oncology Source Type: research

Molecular characterization of Chinese patients with small bowel adenocarcinoma
AbstractPurposeSmall bowel adenocarcinoma (SBA) is a rare malignancy of the gastrointestinal tract, and its unique location within the small intestine presents difficulties in obtaining tissue samples from the lesions. This limitation hinders the research and development of effective clinical treatment methods. Circulating tumor DNA (ctDNA) analysis holds promise as an alternative approach for investigating SBA and guiding treatment decisions, thereby improving the prognosis of SBA.MethodsBetween January 2017 and August 2021, a total of 336 tissue or plasma samples were obtained and the corresponding mutation status in tis...
Source: Clinical and Translational Oncology - March 21, 2024 Category: Cancer & Oncology Source Type: research

Advances in tumor vascular growth inhibition
AbstractTumor growth and metastasis require neovascularization, which is dependent on a complex array of factors, such as the production of various pro-angiogenic factors by tumor cells, intercellular signaling, and stromal remodeling. The hypoxic, acidic tumor microenvironment is not only conducive to tumor cell proliferation, but also disrupts the equilibrium of angiogenic factors, leading to vascular heterogeneity, which further promotes tumor development and metastasis. Anti-angiogenic strategies to inhibit tumor angiogenesis has, therefore, become an important focus for anti-tumor therapy. The traditional approach inv...
Source: Clinical and Translational Oncology - March 20, 2024 Category: Cancer & Oncology Source Type: research

Current status of neoadjuvant immunotherapy for the treatment of gastric cancer
This article summarizes the research progress and controversies associated with neoadjuvant immunotherapy in gastric cancer, aiming to optimize clinical benefits for gastric cancer patients undergoing this treatment approach. The retrieval methods of this study encompassed databases such as PubMed, Google Scholar, Web of Science, clinicaltrials.gov, etc. The retrieved articles included guidelines, consensus, meta-analyses, clinical trials, and reviews related to locally advanced gastric cancer published up to January 2024. (Source: Clinical and Translational Oncology)
Source: Clinical and Translational Oncology - March 20, 2024 Category: Cancer & Oncology Source Type: research